MEI Pharma Company Profile (NASDAQ:MEIP)

About MEI Pharma (NASDAQ:MEIP)

MEI Pharma logoMEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MEIP
  • CUSIP: N/A
  • Web:
  • Market Cap: $77.96 million
  • Outstanding Shares: 36,772,000
Average Prices:
  • 50 Day Moving Avg: $1.62
  • 200 Day Moving Avg: $1.59
  • 52 Week Range: $1.23 - $2.28
  • Trailing P/E Ratio: 62.35
  • Foreward P/E Ratio: -1.53
  • P/E Growth: -985.00
Sales & Book Value:
  • Annual Revenue: $22.8 million
  • Price / Sales: 3.42
  • Book Value: $1.49 per share
  • Price / Book: 1.42
  • EBIDTA: $1.06 million
  • Return on Equity: -7.59%
  • Return on Assets: -6.49%
  • Current Ratio: 17.42%
  • Quick Ratio: 17.42%
  • Average Volume: 161,330 shs.
  • Beta: 1.01
  • Short Ratio: 0.38

Frequently Asked Questions for MEI Pharma (NASDAQ:MEIP)

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The company had revenue of $4.51 million for the quarter, compared to the consensus estimate of $5 million. View MEI Pharma's Earnings History.

Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?

3 equities research analysts have issued 1 year target prices for MEI Pharma's stock. Their forecasts range from $2.00 to $6.50. On average, they anticipate MEI Pharma's share price to reach $4.25 in the next twelve months. View Analyst Ratings for MEI Pharma.

Who are some of MEI Pharma's key competitors?

Who owns MEI Pharma stock?

MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.25%), Vanguard Group Inc. (1.79%), FMR LLC (0.95%), Geode Capital Management LLC (0.38%), Oxford Asset Management (0.30%) and Goldman Sachs Group Inc. (0.22%). View Institutional Ownership Trends for MEI Pharma.

Who bought MEI Pharma stock? Who is buying MEI Pharma stock?

MEI Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management, Goldman Sachs Group Inc., Vanguard Group Inc., TFS Capital LLC, FMR LLC and Geode Capital Management LLC. View Insider Buying and Selling for MEI Pharma.

How do I buy MEI Pharma stock?

Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MEI Pharma stock cost?

One share of MEI Pharma stock can currently be purchased for approximately $2.12.

Analyst Ratings

Consensus Ratings for MEI Pharma (NASDAQ:MEIP) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $4.25 (100.47% upside)

Analysts' Ratings History for MEI Pharma (NASDAQ:MEIP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Oppenheimer Holdings Inc.Initiated CoverageOutperform$6.00 -> $6.50HighView Rating Details
5/24/2017CannReiterated RatingOutperformHighView Rating Details
8/2/2016WedbushReiterated RatingNeutral$2.00N/AView Rating Details
10/7/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
9/2/2015Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for MEI Pharma (NASDAQ:MEIP)
Earnings by Quarter for MEI Pharma (NASDAQ:MEIP)
Earnings History by Quarter for MEI Pharma (NASDAQ:MEIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q3 2017($0.03)($0.02)$5.00 million$4.51 millionViewN/AView Earnings Details
2/8/2017Q217($0.29)$0.32$1.25 million$17.20 millionViewN/AView Earnings Details
11/8/2016Q1 2017($0.14)($0.12)$0.63 million$1.10 millionViewN/AView Earnings Details
9/6/2016Q4 2016($0.20)($0.17)ViewN/AView Earnings Details
9/2/2015Q4 2015($0.23)($0.17)ViewN/AView Earnings Details
9/9/2014Q4 2014($0.37)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MEI Pharma (NASDAQ:MEIP)
Current Year EPS Consensus Estimate: $0.02 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS


Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MEI Pharma (NASDAQ:MEIP)
Insider Ownership Percentage: 4.62%
Institutional Ownership Percentage: 15.01%
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership by Quarter for MEI Pharma (NASDAQ:MEIP)
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2015Vivo Ventures Vii, LlcMajor ShareholderSell390,572$1.84$718,652.48View SEC Filing  
1/21/2015Charles V Baltic IIIDirectorBuy5,000$3.81$19,050.00View SEC Filing  
12/9/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell79,085$6.01$475,300.85View SEC Filing  
12/8/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell9,004$6.05$54,474.20View SEC Filing  
6/30/2014Charles V Baltic IIIDirectorBuy2,000$6.56$13,120.00View SEC Filing  
10/29/2013Vivo Ventures Vii, LlcMajor ShareholderSell299,609$8.21$2,459,789.89View SEC Filing  
10/2/2013Vivo Ventures Vii, LlcMajor ShareholderSell581,646$10.16$5,909,523.36View SEC Filing  
8/16/2013Charles V Baltic IIIDirectorBuy2,600$6.82$17,732.00View SEC Filing  
6/28/2013Vivo Ventures Vii, LlcMajor ShareholderSell7,337$7.58$55,614.46View SEC Filing  
6/11/2013Vivo Ventures V, LlcMajor ShareholderSell13,727$7.80$107,070.60View SEC Filing  
5/16/2013Vivo Ventures Vii, LlcMajor ShareholderSell17,428$9.07$158,071.96View SEC Filing  
5/8/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell200,000$8.58$1,716,000.00View SEC Filing  
1/25/2013Charles V Baltic IIIDirectorBuy10,200$6.04$61,608.00View SEC Filing  
12/21/2012Charles V Baltic IIIDirectorBuy3,500$7.18$25,130.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MEI Pharma (NASDAQ:MEIP)
Latest Headlines for MEI Pharma (NASDAQ:MEIP)
DateHeadline logoCan MEI Pharma Rise Nearly 300%? - May 26 at 7:18 PM logoMEI Pharma Inc (MEIP) Coverage Initiated at Oppenheimer Holdings Inc. - May 25 at 8:51 AM logoMEI Pharma Inc (MEIP) Now Covered by Analysts at Cann - May 24 at 5:16 PM logoCatalyst Pharmaceuticals Focuses on Development of Firdapse - May 23 at 6:00 PM logoCalithera Biosciences (CALA) Jumps: Stock Moves 17% Higher - May 22 at 10:11 AM logoMEI Pharma (MEIP), Helsinn Group Announce Upcoming Presentations at ASCO - - May 19 at 11:03 AM logoHelsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia - May 19 at 11:03 AM logoVertex Ups Kalydeco Sales View as FDA Okays Label Expansion - May 19 at 11:03 AM logoReasons to Add Puma Biotechnology (PBYI) to Portfolio Now - May 17 at 6:28 PM logoMEI Pharma Inc (MEIP) Raised to "Strong-Buy" at Zacks Investment Research - May 9 at 7:36 AM logoMEI Pharma Inc (MEIP) Releases Quarterly Earnings Results, Hits Expectations - May 8 at 7:32 PM logoMEI Pharma Reports Third Quarter Fiscal Year 2017 Results - PR Newswire (press release) - May 5 at 8:44 AM logoMEI Pharma Reports Third Quarter Fiscal Year 2017 Results - May 4 at 11:44 AM logoPositive Press Coverage Extremely Likely to Affect MEI Pharma (MEIP) Share Price - April 29 at 11:58 AM logoMEI Pharma (MEIP) Receiving Very Positive News Coverage, Analysis Finds - April 23 at 8:00 AM logoMEI Pharma (MEIP) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 11:10 AM logo8:02 am MEI Pharma announces appointment of Brian Drazba as CFO - April 4 at 8:48 AM logoMEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - April 4 at 8:48 AM logoMEI Pharma to Present at Needham Healthcare Conference - March 28 at 10:29 AM logoMEI Pharma (MEIP) Presents At Oppenheimer 27th Annual Healthcare Conference - March 22 at 6:37 PM logoMEI Pharma to Present at Oppenheimer Healthcare Conference - March 14 at 11:09 AM logoMEI PHARMA, INC. Financials - February 11 at 6:36 PM logoMEI Pharma Reports Second Quarter Fiscal Year 2017 Results - February 8 at 7:18 PM logoMEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report - February 8 at 7:18 PM



MEI Pharma (MEIP) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff